Interpace Diag Group (IDXG)

$0.77 +0.06 (8.45%)
Market Cap 3.38M
Revenue (ttm) 46.93M
Net Income (ttm) 6.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 14.28%
Debt to Equity Ratio 0.00
Volume 2,009
Avg Vol 10,736
Day's Range N/A - N/A
Shares Out 4.42M
Stochastic %K 6%
Beta 0.73
Analysts Strong Buy
Price Target $11.00

Company Profile

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 776 6419
Address:
Waterview Plaza, Suite 310 2001 Route 46, Parsippany, United States
Waters59
Waters59 Jun. 16 at 1:59 PM
$IDXG Just no volume. Doesn't need much to change the direction. Just sell the company already and let the bleeding stop.
1 · Reply
AlphaTuna
AlphaTuna May. 23 at 12:34 AM
Lowest Volume Rated General Stocks Per 5/22/2025’s Close: 1 – $AHOTF 2 – $CAPC 3 – $AKTSQ 4 – $RDEXF 5 – $PAANF 6 – $FDVA 7 – $FNRN 8 – $IDXG 9 – $ARESF 10 – $CCM https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-5-22-2025/
0 · Reply
Esau815
Esau815 May. 22 at 12:56 PM
$IDXG I'm definitely wait and see on this one as I wait for the next Q. The next Q will be almost pure thyroid as PancraGen was discontinued April 24. Their guidance sort of indicates $8.5MM per Q thyroid sales. Assuming that's sort of on target--what will their EBITDA be? The closer to $2MM per Q the better though that might not be feasible. That's the number I'm looking at. They just missed out paying off the Broad Oak debt by about three months with PancraGen revenues. Those last months of delays were cruicial in getting that debt down. Too bad they couldn't have squeezed out a few more. Thanks to Ampersand/1315 giving up their preference this is definitely one that might have a doable outcome.
0 · Reply
Benderama8
Benderama8 May. 10 at 2:09 AM
$IDXG I'm not sure what to think on this stock other than it's fairly valued at this point. If you include in the preferred shares converting into common, the outstanding shares would be around 29m. Assuming they can make about 1m a quarter, that puts this stock at a p/e of about 8.
1 · Reply
apppro
apppro May. 8 at 8:32 PM
$IDXG could be worse. not really so bad after all
0 · Reply
Waters59
Waters59 May. 2 at 3:47 PM
$IDXG umph, this 1 hurts. Wish their was a buyout of $4, though I need like $16. Hell, I'd take $2.
1 · Reply
Esau815
Esau815 May. 2 at 1:48 AM
$IDXG Quite a filing. "substantially offset"? One third of their revenues is about $16MM No way that the CEO is making a false filing. I consider this filing to be very good news. Let's see if the market agrees.
0 · Reply
Cujo
Cujo May. 1 at 11:09 PM
$IDXG The Company expects that the loss of PancraGEN® and related restructuring activities will reduce its annualized cost of revenue and operating expenses by approximately $12.5 million to $14.5 million which is expected to substantially offset the expected loss of approximately one-third of its revenues. The cost that the Company expects to incur in connection with the Restructuring Plan is subject to several assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Restructuring Plan.
0 · Reply
Esau815
Esau815 Apr. 25 at 3:25 PM
$IDXG Thought that Mr. Market had realized that PancraGen was likely dead before this. Was wrong about that. At this point? Thyroid has $27MM in revenue and CEO says IDXG is profitable without PancraGen. Remember. The preferreds GAVE UP THEIR PREFERENCE. So this will not be a zero. They own 81% of the common. Had they not converted this would be hopeless. At present prices? They have about $3MM in debt which shouldn't be onerous. Have to think that they will have a deal that will yield more than today's price.
1 · Reply
apppro
apppro Apr. 24 at 8:24 PM
$IDXG @InterpaceBio $IDXG Yeah well this sucks: "Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk" thought we had a chance. But CMS is a broken mess. This was expected really. They do say stay profitable and planned without it. so ...........
1 · Reply
Latest News on IDXG
No data available.
Waters59
Waters59 Jun. 16 at 1:59 PM
$IDXG Just no volume. Doesn't need much to change the direction. Just sell the company already and let the bleeding stop.
1 · Reply
AlphaTuna
AlphaTuna May. 23 at 12:34 AM
Lowest Volume Rated General Stocks Per 5/22/2025’s Close: 1 – $AHOTF 2 – $CAPC 3 – $AKTSQ 4 – $RDEXF 5 – $PAANF 6 – $FDVA 7 – $FNRN 8 – $IDXG 9 – $ARESF 10 – $CCM https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-5-22-2025/
0 · Reply
Esau815
Esau815 May. 22 at 12:56 PM
$IDXG I'm definitely wait and see on this one as I wait for the next Q. The next Q will be almost pure thyroid as PancraGen was discontinued April 24. Their guidance sort of indicates $8.5MM per Q thyroid sales. Assuming that's sort of on target--what will their EBITDA be? The closer to $2MM per Q the better though that might not be feasible. That's the number I'm looking at. They just missed out paying off the Broad Oak debt by about three months with PancraGen revenues. Those last months of delays were cruicial in getting that debt down. Too bad they couldn't have squeezed out a few more. Thanks to Ampersand/1315 giving up their preference this is definitely one that might have a doable outcome.
0 · Reply
Benderama8
Benderama8 May. 10 at 2:09 AM
$IDXG I'm not sure what to think on this stock other than it's fairly valued at this point. If you include in the preferred shares converting into common, the outstanding shares would be around 29m. Assuming they can make about 1m a quarter, that puts this stock at a p/e of about 8.
1 · Reply
apppro
apppro May. 8 at 8:32 PM
$IDXG could be worse. not really so bad after all
0 · Reply
Waters59
Waters59 May. 2 at 3:47 PM
$IDXG umph, this 1 hurts. Wish their was a buyout of $4, though I need like $16. Hell, I'd take $2.
1 · Reply
Esau815
Esau815 May. 2 at 1:48 AM
$IDXG Quite a filing. "substantially offset"? One third of their revenues is about $16MM No way that the CEO is making a false filing. I consider this filing to be very good news. Let's see if the market agrees.
0 · Reply
Cujo
Cujo May. 1 at 11:09 PM
$IDXG The Company expects that the loss of PancraGEN® and related restructuring activities will reduce its annualized cost of revenue and operating expenses by approximately $12.5 million to $14.5 million which is expected to substantially offset the expected loss of approximately one-third of its revenues. The cost that the Company expects to incur in connection with the Restructuring Plan is subject to several assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Restructuring Plan.
0 · Reply
Esau815
Esau815 Apr. 25 at 3:25 PM
$IDXG Thought that Mr. Market had realized that PancraGen was likely dead before this. Was wrong about that. At this point? Thyroid has $27MM in revenue and CEO says IDXG is profitable without PancraGen. Remember. The preferreds GAVE UP THEIR PREFERENCE. So this will not be a zero. They own 81% of the common. Had they not converted this would be hopeless. At present prices? They have about $3MM in debt which shouldn't be onerous. Have to think that they will have a deal that will yield more than today's price.
1 · Reply
apppro
apppro Apr. 24 at 8:24 PM
$IDXG @InterpaceBio $IDXG Yeah well this sucks: "Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk" thought we had a chance. But CMS is a broken mess. This was expected really. They do say stay profitable and planned without it. so ...........
1 · Reply
crane_train21
crane_train21 Apr. 24 at 8:16 PM
$IDXG well that’s a problem.
1 · Reply
Waters59
Waters59 Apr. 24 at 6:02 PM
$IDXG no news...no volume...🚮
0 · Reply
Cujo
Cujo Apr. 8 at 5:03 PM
$IDXG finally some volume
0 · Reply
WAYWARD_SUN
WAYWARD_SUN Apr. 8 at 6:17 AM
$IDXG
0 · Reply
PenkeTrading
PenkeTrading Apr. 8 at 6:05 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Interpace Biosciences Inc. Is that bullish or bearish? $IDXG #RsiOversold #OTCQX
0 · Reply
Esau815
Esau815 Apr. 1 at 1:07 PM
$IDXG The BIG UNKNOWN is of course PancraGen reimbursement. The present deadline is April 24. Even if they kick the can down the road and extend it, it would have a huge impact on IDXG in that they're able to pay down the BroadOak debt. Two events saved IDXG from being a zero. The appeal/delay enabled debt to be pared down from $12MM to $4.4MM on 12/31 and likely about $2.7MM today. The second event was the preferred B converting to preferred C but giving up their liquidation preference. If the preference were in place, the common would be worthless. Worst case scenario is VERY bad for the employees. But common exit strategy is not a zero. Figure thyroid is $30MM of the $47MM. Put even a one handle on it and you have more than $1 per share. A two handle would be $2 per share. That's after the $2.7MM debt is paid. EBITDA hard to gauge. $9MM now. Let's cut that in half. $30MM would be 6 EBITDA.
0 · Reply
Cujo
Cujo Apr. 1 at 1:00 AM
$IDXG Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results 01/31/25 8:30 AM ●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels
0 · Reply
apppro
apppro Mar. 31 at 7:17 PM
$IDXG any reason for today's sell off
1 · Reply
Cujo
Cujo Mar. 8 at 4:54 PM
$IDXG from the latest 8k....Accordingly, investors should no longer rely upon such financial statements. The reversal of accrued royalties expense is a result of the Company’s determination that the accrual of such royalties expenses was not required. The reversal is expected to have a positive impact on various financial statement items, including current liabilities, stockholders’ equity (deficit) and net income.
1 · Reply
Waters59
Waters59 Mar. 3 at 3:07 PM
$IDXG who or how do you contact stocktwits get get this ticker to work? Hasn't updated in a week.
0 · Reply
Cujo
Cujo Feb. 7 at 5:55 PM
$IDXG Bollinger bands are being collapsed, news coming?
1 · Reply
apppro
apppro Jan. 31 at 1:46 PM
$IDXG Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results ●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels $IDXG
0 · Reply